Mepolizumab versus placebo for asthma

Powell, Colin, Milan, Stephen J., Dwan, Kerry, Bax, Lynne and Walters, Nicola 2015. Mepolizumab versus placebo for asthma. Cochrane Database of Systematic Reviews (7) , CD010834. 10.1002/14651858.CD010834.pub2

Preview

PDF - Published Version Download (865kB) | Preview

Abstract

Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation. Recent studies have suggested these agents may have a role in reducing exacerbations and improving health-related quality of life (HRQoL). There are no recommendations for the use of mepolizumab in adults or children in the recent update of the BTS/SIGN guidelines (BTS/SIGN 2014). Objectives To compare the effects of mepolizumab with placebo on exacerbations and HRQoL in adults and children with chronic asthma. Search methods We searched the Cochrane Airways Group Register (CAGR) of trials, clinical trial registries, manufacturers' websites and the reference lists of included studies. Searches were conducted in November 2013 and updated in November 2014. Selection criteria We included randomised controlled trials comparing mepolizumab versus placebo in adults and children with asthma. Data collection and analysis Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected by The Cochrane Collaboration.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Cochrane Collaboration
ISSN:	1469-493X
Date of First Compliant Deposit:	19 May 2016
Last Modified:	14 May 2023 15:28
URI:	https://orca.cardiff.ac.uk/id/eprint/91056

Citation Data

Cited 29 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item